Viemed Healthcare (NASDAQ:VMD) Earns Hold (C) Rating from Weiss Ratings

Key Points

• Viemed Healthcare's stock has been given a "hold (c)" rating by Weiss Ratings, indicating a cautious outlook for investors.
• The company's stock recently traded at $6.88, and its market capitalization stands at $266.68 million.
• Viemed reported $0.08 EPS for the last quarter, meeting analyst expectations, but fell short on revenue with $63.06 million reported against a projection of $63.50 million.

Viemed Healthcare (NASDAQ:VMD - Get Free Report)'s stock had its "hold (c)" rating restated by equities research analysts at Weiss Ratings in a research report issued to clients and investors on Tuesday,Weiss Ratings reports.

Viemed Healthcare Stock Performance

Shares of NASDAQ:VMD traded down $0.01 during trading on Tuesday, hitting $6.88. 45,980 shares of the company traded hands, compared to its average volume of 179,858. The stock has a market capitalization of $266.68 million, a price-to-earnings ratio of 20.22 and a beta of 1.30. The business's fifty day moving average is $6.90 and its 200-day moving average is $6.79. Viemed Healthcare has a one year low of $5.93 and a one year high of $9.81. The company has a quick ratio of 1.37, a current ratio of 1.48 and a debt-to-equity ratio of 0.02.

Viemed Healthcare (NASDAQ:VMD - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.08 EPS for the quarter, meeting the consensus estimate of $0.08. The company had revenue of $63.06 million during the quarter, compared to analyst estimates of $63.50 million. Viemed Healthcare had a return on equity of 10.38% and a net margin of 5.80%.

Insider Buying and Selling

In other Viemed Healthcare news, VP Jerome Cambre sold 4,880 shares of the company's stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $7.32, for a total value of $35,721.60. Following the completion of the sale, the vice president directly owned 84,191 shares in the company, valued at $616,278.12. This represents a 5.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, President Michael Moore sold 50,090 shares of the company's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $7.33, for a total value of $367,159.70. Following the completion of the transaction, the president directly owned 126,343 shares in the company, valued at $926,094.19. This represents a 28.39% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 20.00% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC bought a new position in shares of Viemed Healthcare in the first quarter valued at $90,000. Corton Capital Inc. boosted its position in shares of Viemed Healthcare by 45.4% in the first quarter. Corton Capital Inc. now owns 14,842 shares of the company's stock worth $108,000 after buying an additional 4,634 shares during the period. EntryPoint Capital LLC boosted its position in shares of Viemed Healthcare by 36.9% in the first quarter. EntryPoint Capital LLC now owns 15,706 shares of the company's stock worth $114,000 after buying an additional 4,232 shares during the period. Cardinal Point Capital Management ULC acquired a new stake in shares of Viemed Healthcare in the second quarter worth $128,000. Finally, Intech Investment Management LLC raised its holdings in shares of Viemed Healthcare by 14.4% during the second quarter. Intech Investment Management LLC now owns 18,612 shares of the company's stock worth $129,000 after acquiring an additional 2,349 shares in the last quarter. Institutional investors own 74.24% of the company's stock.

About Viemed Healthcare

Viemed Healthcare, Inc, together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.